Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

52.95
-0.1582-0.30%
Post-market: 52.92-0.0316-0.06%19:30 EDT
Volume:6K
Turnover:303.64K
Market Cap:178.45M
PE:- -
High:53.80
Open:53.80
Low:52.92
Close:53.11
52wk High:56.45
52wk Low:39.08
Shares:3.37M
Float Shares:3.37M
Volume Ratio:0.52
T/O Rate:0.17%
Dividend:0.00
Dividend Rate:0.01%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Molina Healthcare Earnings Beat Estimates. the Medicaid Insurer is Confronting Investor Doubts.

Dow Jones
·
Jul 23

Molina Healthcare Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 23

Corcept Therapeutics to Announce Second Quarter Financial Results

Reuters
·
Jul 23

Molina Healthcare Posts Lower 2Q Profit, Rev as Membership Declines

Dow Jones
·
Jul 23

Molina Healthcare Q2 FY26 GAAP EPS Drops 74% to $1.19; Revenue Falls 4.8% to $10.87 Billion

Reuters
·
Jul 23

Molina Healthcare: FY Guidance Also Includes Loss of $1.00 Per Share Due to Performance of Traditional Mapd Product

THOMSON REUTERS
·
Jul 23

Molina Healthcare Inc Outlook Full Year 2026 Adjusted Earnings to at Least $5.25 Per Diluted Share

THOMSON REUTERS
·
Jul 23

Molina Healthcare - Fy2026 Premium Revenue Guidance Unchanged at Approx $42 Bln

THOMSON REUTERS
·
Jul 23

Molina Healthcare: FY Guidance Includes Loss of $1.50 Per Share Due to Implementation of New Florida Medicaid Contract in Q4

THOMSON REUTERS
·
Jul 23

Molina Healthcare Inc: Medicaid Mcr for Q2 of 2026 was 92.7%

THOMSON REUTERS
·
Jul 23

Molina Healthcare - Q2 2026 Premium Revenue About $10.20 Bln

THOMSON REUTERS
·
Jul 23

Molina Healthcare Q2 Premium Revenue USD 10,244 Million

THOMSON REUTERS
·
Jul 23

Molina Healthcare Q2 EPS USD 1.19

THOMSON REUTERS
·
Jul 23

Corcept Therapeutics Schedules Second-quarter Results Conference Call

Reuters
·
Jul 23

Why Molina Healthcare (MOH) Is Down 6.2% After S&P Index Shift And Rising Profit Concerns

Simply Wall St.
·
Jul 22

This Medicaid Insurer's Stock Has Climbed in 2026. Investors Still Have Doubts.

Dow Jones
·
Jul 22

Is Krystal Biotech (KRYS) Overvalued On Its KB801 Patent Data Update?

Simply Wall St.
·
Jul 22

Krystal Biotech - Discontinues Clinical Study to Advance KB801 into Pivotal Trial; no Safety Concerns Observed - SEC Filing

THOMSON REUTERS
·
Jul 22

Krystal Biotech - no Further Subject-level Updates from Discontinued Study; Pivotal Trial Results Expected in Due Course - SEC Filing

THOMSON REUTERS
·
Jul 22

Krystal Biotech - Files Response with Uspto on KB801 Patent Application - SEC Filing

THOMSON REUTERS
·
Jul 22